These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31843269)

  • 21. Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
    Coronel D; García-Rivera EJ; Rivera DM; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Wang H; Pagnon A; Jantet-Blaudez F; Peñalosa LAR; Dayan G; Zambrano B; DiazGranados CA; Noriega F
    Pediatr Infect Dis J; 2020 Oct; 39(10):961-968. PubMed ID: 32932330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
    Torresi J; Heron LG; Qiao M; Marjason J; Chambonneau L; Bouckenooghe A; Boaz M; van der Vliet D; Wallace D; Hutagalung Y; Nissen MD; Richmond PC
    Vaccine; 2015 Sep; 33(39):5127-34. PubMed ID: 26279339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
    Tricou V; Winkle PJ; Tharenos LM; Rauscher M; Escudero I; Hoffman E; LeFevre I; Borkowski A; Wallace D
    Vaccine; 2023 Nov; 41(47):6999-7006. PubMed ID: 37884415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.
    Lin TH; Chen HW; Hsiao YJ; Yan JY; Chiang CY; Chen MY; Hu HM; Wu SH; Pan CH
    Front Immunol; 2020; 11():546. PubMed ID: 32300346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial.
    Turner M; Papadimitriou A; Winkle P; Segall N; Levin M; Doust M; Johnson C; Lucksinger G; Fierro C; Pickrell P; Raanan M; Tricou V; Borkowski A; Wallace D
    Hum Vaccin Immunother; 2020 Oct; 16(10):2456-2464. PubMed ID: 32119591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
    Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
    Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
    Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
    Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
    Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
    Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a single dose, live-attenuated 'tetravalent dengue vaccine' in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial.
    Mohanty L; Prabhu M; Kumar Mishra A; Purty AJ; Kanungo R; Ghosh G; Prahan Kumar R; Newton Raj A; Bhushan S; Kumar Jangir M; Gupta A; Bhakri A
    Vaccine X; 2022 Apr; 10():100142. PubMed ID: 35252836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
    Sun W; Cunningham D; Wasserman SS; Perry J; Putnak JR; Eckels KH; Vaughn DW; Thomas SJ; Kanesa-Thasan N; Innis BL; Edelman R
    Hum Vaccin; 2009; 5(1):33-40. PubMed ID: 18670195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
    Coronel-Martinez DL; Park J; López-Medina E; Capeding MR; Bonfanti AAC; Montalbán MC; Ramírez I; Gonzales MLA; Zambrano B; Dayan G; Chen Z; Wang H; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2022 Jun; 22(6):901-911. PubMed ID: 35364022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
    Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT
    Lancet Infect Dis; 2014 Sep; 14(9):830-8. PubMed ID: 25087476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
    Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
    J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
    Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
    Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
    Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
    J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.
    Park J; Archuleta S; Oh MH; Shek LP; Wang H; Bonaparte M; Frago C; Bouckenooghe A; Jantet-Blaudez F; Begue S; Gimenez-Fourage S; Pagnon A
    Hum Vaccin Immunother; 2021 Jul; 17(7):2107-2116. PubMed ID: 33626291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
    Kallas EG; Precioso AR; Palacios R; Thomé B; Braga PE; Vanni T; Campos LMA; Ferrari L; Mondini G; da Graça Salomão M; da Silva A; Espinola HM; do Prado Santos J; Santos CLS; Timenetsky MDCST; Miraglia JL; Gallina NMF; Weiskopf D; Sette A; Goulart R; Salles RT; Maestri A; Sallum AME; Farhat SCL; Sakita NK; Ferreira JCOA; Silveira CGT; Costa PR; Raw I; Whitehead SS; Durbin AP; Kalil J
    Lancet Infect Dis; 2020 Jul; 20(7):839-850. PubMed ID: 32220283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
    Tricou V; Eyre S; Ramjee M; Collini P; Mojares Z; Loeliger E; Mandaric S; Rauscher M; Brose M; Lefevre I; Folschweiller N; Wallace D
    Vaccine; 2023 Feb; 41(7):1398-1407. PubMed ID: 36681529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.